secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200220
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics board approves dissolution; CFO and CLO positions eliminated
--------------------------------------------------------------------------------

- Board unanimously approved Plan of Liquidation and Dissolution; special stockholder meeting on or around Oct 17, 2024.
- Workforce reduced to 3 employees; CFO Chris Degnan and CLO Jennifer Evans Stacey positions cut effective Aug 31, 2024.
- Q2 2024 net loss $4.1M ($0.07 per share) vs $20.7M ($0.48) in Q2 2023; R&D expenses fell to $1.4M.
- Cash and equivalents $10.7M as of June 30, 2024; expects to fund dissolution costs for at least 12 months.
- No suitable strategic alternatives found; may still sell pipeline assets, proceeds to be distributed to stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524200220/0001193125-24-200220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524200220/d879192d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer